アトピー性皮膚炎の世界市場レポート 2024年

アトピー性皮膚炎の市場規模は近年急速に拡大しています。2023年の75億1,000万米ドルから2024年には87億米ドルへと、CAGR15.9％で拡大します。過去に観察された成長は、アトピー性皮膚炎に対する医学的理解と認知度の向上、罹患率と有病率の変化、患者擁護と支援の存在、治療選択肢の進化、この分野における継続的な研究開発などの要因によるものと考えられます。

2023年のアトピー性皮膚炎市場で最大の地域は北米でした。アジア太平洋は予測期間中に最も急成長する地域となる見込みです。アトピー性皮膚炎市場レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界のアトピー性皮膚炎市場の促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界のアトピー性皮膚炎市場規模実績と成長、2018～2023年
• 世界のアトピー性皮膚炎市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界のアトピー性皮膚炎市場、薬剤クラス別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• コルチコステロイド
• エモリエント剤/保湿剤
• IL-4とPDE4阻害剤
• カルシニューリン阻害剤
• 抗生物質
• その他
• 世界のアトピー性皮膚炎市場、投与方法別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 話題
• 注射
• 経口
• 世界のアトピー性皮膚炎市場、流通チャネル別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院薬局
• 小売薬局
• オンライン薬局

第7章 地域と国の分析

• 世界のアトピー性皮膚炎市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界のアトピー性皮膚炎市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• アトピー性皮膚炎市場の競合情勢
• アトピー性皮膚炎市場企業プロファイル
  • Sanofi SA
  • Meda AB
  • Regeneron Pharmaceuticals Inc.
  • Novartis International AG
  • Pfizer Inc.

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の展望と潜在性分析

第35章 付録

Atopic Dermatitis Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on atopic dermatitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for atopic dermatitis? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The atopic dermatitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Drug Class: Corticosteroids; Emollients/Moisturizers; IL-4 and PDE4 Inhibitors; Calcineurin Inhibitors; Antibiotics; Other Drug Classes
• 2) By Mode of Administration: Topical; Injectable; Oral
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Companies Mentioned: Sanofi SA; Meda AB; Regeneron Pharmaceuticals Inc.; Novartis International AG; Pfizer Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Atopic dermatitis is a chronic dermatological condition characterized by skin dryness and itching. This condition progresses over time and is not contagious through contact.

The main drug classes used to treat atopic dermatitis include corticosteroids, emollients/moisturizers, IL-4 and PDE4 inhibitors, calcineurin inhibitors, antibiotics, and others. Corticosteroids are anti-inflammatory drugs that mimic cortisol and are employed in the treatment of various diseases, including rheumatological conditions, rheumatoid arthritis, lupus, and atopic dermatitis. These drugs can be administered through various modes, such as topical, injectable, and oral, and are available through different distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The atopic dermatitis market research report is one of a series of new reports from The Business Research Company that provides atopic dermatitis market statistics, including atopic dermatitis industry global market size, regional shares, competitors with an atopic dermatitis market share, detailed atopic dermatitis market segments, market trends and opportunities, and any further data you may need to thrive in the atopic dermatitis industry. This atopic dermatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The atopic dermatitis market size has grown rapidly in recent years. It will grow from $7.51 billion in 2023 to $8.7 billion in 2024 at a compound annual growth rate (CAGR) of 15.9%. The observed growth in the historic period can be attributed to factors such as increased medical understanding and awareness of atopic dermatitis, changes in incidence and prevalence rates, the presence of patient advocacy and support, the evolution of treatment options, and ongoing research and development in the field.

The atopic dermatitis market size is expected to see rapid growth in the next few years. It will grow to $15.27 billion in 2028 at a compound annual growth rate (CAGR) of 15.1%. The anticipated growth in the forecast period can be attributed to advancements in biologic therapies, the development of immunomodulators and small molecule drugs, the emergence of pediatric-specific treatments, innovations in gene therapy and precision medicine, and the integration of digital health solutions. Major trends expected in the forecast period include technological advancements in topical treatments, a focus on pediatric care, increased emphasis on environmental and allergen management, and the use of precision diagnosis tools.

The atopic dermatitis market is poised for significant growth due to the high prevalence of this condition, commonly known as eczema. Atopic dermatitis is characterized by skin dryness and itching, necessitating increased attention for diagnosis and treatment. For instance, the National Eczema Association reported that in 2021, approximately 31.6 million people in the US, constituting around 10% of the population, were affected by eczema, with 9.6 million being children under 18. This emphasizes the urgency for effective measures in managing atopic dermatitis, especially since 80% of those affected experience symptoms before the age of 6. Consequently, the rising prevalence of atopic dermatitis continues to drive growth within the atopic dermatitis market.

The growing demand for personalized medicine is anticipated to contribute significantly to the expansion of the atopic dermatitis market. Personalized medicine involves tailoring medical interventions, including drug therapies, to suit individual patient characteristics, such as genetics and molecular factors. This approach ensures more targeted and effective treatments while minimizing adverse effects. For example, as of October 2022, reports indicated a vast array of over 75,000 genetic testing products and 300 personalized medicines, underlining the surging demand for tailored therapeutic options. This trend is fueling the growth of the atopic dermatitis market by emphasizing more precise and patient-centric treatment approaches.

Innovations in product development are emerging as a pivotal trend within the atopic dermatitis market, with major companies introducing novel solutions to reinforce their market position. Notably, in June 2022, Regeneron Pharmaceuticals Inc., a prominent US-based biotechnology company, secured FDA approval for Dupixent (dupilumab). Dupixent is a medication designed for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis. This groundbreaking drug works by inhibiting the signaling of two critical Type 2 inflammatory sources (IL-4 and IL-13), contributing to the development of various conditions such as eosinophilic esophagitis, prurigo nodularis, chronic rhinosinusitis with nasal polyposis, and asthma. The approval of Dupixent represents a significant advancement in pediatric atopic dermatitis treatment, promising more effective therapeutic options for young patients.

Major companies within the atopic dermatitis market are strategically pursuing product approvals to stimulate revenue growth within their industry. Product approvals signify the official endorsement granted by health regulatory bodies, affirming the safety and effectiveness of pharmaceuticals or treatments for managing inflammatory skin conditions like atopic dermatitis. Notably, in January 2022, AbbVie Inc., a prominent US-based pharmaceutical company, secured FDA approval for Rinvoq. Rinvoq, containing upadacitinib as its active component, belongs to the class of janus kinase (JAK) inhibitors, a targeted synthetic disease-modifying antirheumatic drug. This medication received approval for treating moderate-to-severe atopic dermatitis in both adults and children aged 12 years and above. Rinvoq serves as an alternative when other treatments, including biologic medicines or conventional medications, have been ineffective in managing the condition, or when their usage is not recommended. It is noteworthy that Rinvoq (upadacitinib) can be administered in conjunction with methotrexate or as monotherapy, thereby broadening treatment options for atopic dermatitis patients.

In September 2022, Arcutis Biotherapeutics, a prominent commercial-stage biopharmaceuticals firm headquartered in the United States, finalized the acquisition of Ducentis BioTherapeutics for an undisclosed sum. This strategic acquisition is envisioned to reinforce Arcutis Biotherapeutics' position within the medical dermatology sector while enhancing its capacity to address the unmet medical needs of patients dealing with dermatological conditions. Notably, Ducentis BioTherapeutics, a preclinical-stage biotechnology company also based in the US, specializes in the development of primary treatments targeting atopic dermatitis, aligning with Arcutis Biotherapeutics' commitment to advancing therapies for this skin disorder.

Major companies operating in the atopic dermatitis market report are Sanofi SA, Meda AB, Regeneron Pharmaceuticals Inc., Novartis International AG, Pfizer Inc., AbbVie Inc., Astellas Pharma Inc., Arcutis Biotherapeutics Inc., Asana Biosciences LLC, Dermavant Sciences Inc., Eli Lilly and Company, Galderma SA, Incyte Corporation, Bayer AG, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, F Hoffmann-La Roche AG, LEO Pharma A/S, Teva Pharmaceutical Industries Ltd., Mylan MV, Allergan PLC, Encore Dermatology Inc., Menlo Therapeutics Inc., Johnson & Johnson, Merck & Co Inc., Roche Holding AG, Valeant Pharmaceuticals International Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eisai Co. Ltd., Gilead Sciences Inc., Ipsen Biopharmaceuticals Inc., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals Limited

North America was the largest region in the atopic dermatitis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atopic dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the atopic dermatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The atopic dermatitis market consists of sales of biologics, CNI immunosuppressant drugs, and skin barrier emollients. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Atopic Dermatitis Market Characteristics

3. Atopic Dermatitis Market Trends And Strategies

4. Atopic Dermatitis Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Atopic Dermatitis Market Size and Growth

• 5.1. Global Atopic Dermatitis Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Atopic Dermatitis Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Atopic Dermatitis Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Atopic Dermatitis Market Segmentation

• 6.1. Global Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Corticosteroids
• Emollients/Moisturizers
• IL-4 and PDE4 Inhibitors
• Calcineurin Inhibitors
• Antibiotics
• Other Drug Classes
• 6.2. Global Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Topical
• Injectable
• Oral
• 6.3. Global Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

7. Atopic Dermatitis Market Regional And Country Analysis

• 7.1. Global Atopic Dermatitis Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Atopic Dermatitis Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Atopic Dermatitis Market

• 8.1. Asia-Pacific Atopic Dermatitis Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Atopic Dermatitis Market

• 9.1. China Atopic Dermatitis Market Overview
• 9.2. China Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Atopic Dermatitis Market

• 10.1. India Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Atopic Dermatitis Market

• 11.1. Japan Atopic Dermatitis Market Overview
• 11.2. Japan Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Atopic Dermatitis Market

• 12.1. Australia Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Atopic Dermatitis Market

• 13.1. Indonesia Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Atopic Dermatitis Market

• 14.1. South Korea Atopic Dermatitis Market Overview
• 14.2. South Korea Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Atopic Dermatitis Market

• 15.1. Western Europe Atopic Dermatitis Market Overview
• 15.2. Western Europe Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Atopic Dermatitis Market

• 16.1. UK Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Atopic Dermatitis Market

• 17.1. Germany Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Atopic Dermatitis Market

• 18.1. France Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Atopic Dermatitis Market

• 19.1. Italy Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Atopic Dermatitis Market

• 20.1. Spain Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Atopic Dermatitis Market

• 21.1. Eastern Europe Atopic Dermatitis Market Overview
• 21.2. Eastern Europe Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Atopic Dermatitis Market

• 22.1. Russia Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Atopic Dermatitis Market

• 23.1. North America Atopic Dermatitis Market Overview
• 23.2. North America Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Atopic Dermatitis Market

• 24.1. USA Atopic Dermatitis Market Overview
• 24.2. USA Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Atopic Dermatitis Market

• 25.1. Canada Atopic Dermatitis Market Overview
• 25.2. Canada Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Atopic Dermatitis Market

• 26.1. South America Atopic Dermatitis Market Overview
• 26.2. South America Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Atopic Dermatitis Market

• 27.1. Brazil Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Atopic Dermatitis Market

• 28.1. Middle East Atopic Dermatitis Market Overview
• 28.2. Middle East Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Atopic Dermatitis Market

• 29.1. Africa Atopic Dermatitis Market Overview
• 29.2. Africa Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Atopic Dermatitis Market Competitive Landscape And Company Profiles

• 30.1. Atopic Dermatitis Market Competitive Landscape
• 30.2. Atopic Dermatitis Market Company Profiles
  • 30.2.1. Sanofi SA
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Meda AB
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Regeneron Pharmaceuticals Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Novartis International AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Pfizer Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Atopic Dermatitis Market Competitive Benchmarking

32. Global Atopic Dermatitis Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Atopic Dermatitis Market

34. Atopic Dermatitis Market Future Outlook and Potential Analysis

• 34.1 Atopic Dermatitis Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Atopic Dermatitis Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Atopic Dermatitis Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer